Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
Key Highlights
- ➤Updated AlloNK data covers at least 20 refractory RA patients with six months’ follow-up
- ➤Updated data covers 11 Sjögren disease and at least five systemic sclerosis patients
- ➤AlloNK plus rituximab shows deep B-cell depletion across immune-mediated diseases
- ➤Phase 3 refractory RA registrational trial planned to initiate during the second half of 2026
- ➤Live webcast scheduled November 9, 2026, including data from at least 10 Phase 3-eligible RA patients
Expert Statements
Guillermo J. Valenzuela, Medical Director, Integral Rheumatology & Immunology Specialists
“Outpatient-Administered, Non-Genetically Modified NK Cells in Combination with Rituximab Generate Robust Efficacy Responses Comparable with Autologous CAR T in 34 Patients with Rheumatologic Diseases”
Subhashis Banerjee, Chief Medical Officer, Artiva Biotherapeutics
“Outpatient-Administered, Non-Genetically Modified NK Cells in Combination with Rituximab, Demonstrates Favorable Safety Profile in a Large Cohort of 60 Patients with Rheumatological Diseases while Consistently Achieving Deep B-cell Depletion”
Jonathan Kay, Timothy S. and Elaine L. Peterson Chair in Rheumatology, UMass Chan Medical School
“High Unmet Need and Low Clinical Response Rates Among Rheumatoid Arthritis Patients Failing Two or More Classes of b/tsDMARDs: A United States Registry Analysis”
* Oral presentation highlighting updated clinical data from at least 20 patients with refractory rheumatoid arthritis (RA), 11 patients with Sjögren disease (SjD) and at least five patients with systemic sclerosis (SSc) treated with AlloNK plus rituximab in the ongoing Phase 2a basket trial, all with at least six months of follow-up
* Poster presentation highlighting deep, consistent B-cell depletion comparable to that observed with CD19 CAR T-cell therapies and a favorable tolerability profile across immune-mediated diseases
Get started
Create a free account to read the full story.